Strong Medicare Outlook Drives Wells Fargo’s Bullish Upgrade on Humana
Analyst highlights improving Medicare margins and star ratings for stronger 2028 earnings.
/ 124 items
#XY Analyst Up/Down↓
Goldman Sachs Initiates Coverage on Stoke Therapeutics with Buy Rating and $44 Price Target
The firm sees strong potential for zorevunersen in treating Dravet syndrome.
First New Essential Tremor Therapy in 50+ Years: Goldman Bullish on Praxis Precision
Strong outlook for ulixacaltamide and relutrigine approvals by early 2027.
Analyst Upgrade Boosts BeOne Medicines as Brukinsa Outlook Strengthens
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.
Oppenheimer Initiates Outperform Coverage on Connect Biopharma with $8 Target, Implies 3.6x Upside
Rademikibart’s rapid action in acute asthma & COPD positions it for major upside ahead of Phase 2 readouts.
Wolfe Research Upgrades Sarepta to Outperform as DM1 and FSHD Catalysts Approach
With key MAD data for DM1 and FSHD siRNA programs expected in H2 2026, SRPT stock shows strong growth potential.